Revance

Yahoo Finance • 12 months ago

Q3 2023 Revance Therapeutics Inc Earnings Call

Participants Dustin S. Sjuts; President; Revance Therapeutics, Inc. Jessica Serra; Head of IR & ESG; Revance Therapeutics, Inc. Mark J. Foley; CEO & Director; Revance Therapeutics, Inc. Tobin C. Schilke; CFO & Principal Accounting Offi... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC). Such investors are advised to contact Robert S. Willoughb... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC).   Such investors are advised to contact Robert S. Willoug... Full story

Yahoo Finance • last year

13 Stocks to Buy with Exponential Growth

In this article, we will take a look at the 13 stocks to buy with exponential growth. To see more such companies, go directly to 5 Stocks to Buy with Exponential Growth. Optimism was prevailing in the US stock market on October 11 as inve... Full story

Yahoo Finance • last year

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Revance Therapeutics, Inc. - RVNC

NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC).   Such investors are advised to contact Robert S. Willou... Full story

Yahoo Finance • last year

Revance Therapeutics (RVNC) Shares Declined on Profit-Taking

Baron Funds, an investment management company, released its “Baron Discovery Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here. The fund was up 3.58% (Institutional Shares) in the second quarter trailing... Full story

Yahoo Finance • last year

10 Best Revenue Growth Stocks to Buy

In this piece, we will take a look at the ten best revenue growth stocks to buy. If you want to skip over the latest news for the stock market and want to jump ahead to the top five stocks in this list, then take a look at 5 Best Revenue G... Full story

Yahoo Finance • 2 years ago

Revance to Participate in the 43rd Annual Cowen Healthcare Conference

NASHVILLE, Tenn., February 27, 2023--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the 43rd Annual Cowen Healthcare Conference, taking place March 6-8, 2023, in Boston, Massachuset... Full story

Yahoo Finance • 2 years ago

Revance Therapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Revance Therapeutics (NASDAQ:RVNC) Third Quarter 2022 Results Key Financial Results Revenue: US$29.0m (up 47% from 3Q 2021). Net loss: US$84.7m (loss widened by 14% from 3Q 2021). US$1.17 loss per share (further deteriorated from US$1.10... Full story

Yahoo Finance • 2 years ago

FDA Approves New Botox Rival

Analysts say the drug, from Revance Therapeutics, poses a threat to the market-dominating antiwrinkle treatment because it promises to last longer.... Full story

Yahoo Finance • 2 years ago

Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results

Approved label includes full 36-week efficacy data from Phase 3 SAKURA clinical program, positioning DAXXIFY™ as the first and only long-acting neuromodulator that demonstrates a median duration of six months and up to nine months for some... Full story

Yahoo Finance • 3 years ago

Revance to Present New Clinical Data on DaxibotulinumtoxinA for Injection from the ASPEN Phase 3 Program at the 2022 American Academy of Neurology Annual Meeting

- Two presentations highlighting data on DaxibotulinumtoxinA for Injection, including Revance’s first oral presentation of the ASPEN-1 Phase 3 clinical trial data, and one poster detailing the positive topline results from the ASPEN Open L... Full story